Thus, the combination of OX40L/PPT with PD-1 immune checkpoint blockade resulted in significant treatment efficiency enhancement in CT26 subcutaneous colon cancer model, and led to protective immunity against CT26gfp colon cancer cells. This evidence concerns the gene TNFSF4 and colonic neoplasm.